Weiss Ratings Reaffirms Sell (D-) Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Key Points

• Weiss Ratings has restated a "sell (D-)" rating for Alnylam Pharmaceuticals, indicating ongoing concerns about the company’s stock performance.
• Despite Weiss's rating, a consensus of analysts still offers a "Moderate Buy" rating and a target price of $466.92 for Alnylam, with 23 analysts rating it as a Buy.
• Alnylam reported a quarterly EPS of $0.32, significantly beating expectations and showing a 17.3% increase in revenue year-over-year.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.

ALNY has been the topic of a number of other reports. Needham & Company LLC increased their price target on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a "buy" rating in a research report on Thursday, July 31st. Wolfe Research raised Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research note on Monday, August 4th. Morgan Stanley increased their price objective on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the company an "equal weight" rating in a research note on Monday, October 6th. BMO Capital Markets increased their price objective on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an "outperform" rating in a research note on Friday, September 5th. Finally, Stifel Nicolaus increased their price objective on Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the company a "buy" rating in a research note on Monday, October 6th. Twenty-three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $466.92.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY traded down $3.12 on Friday, reaching $460.88. 462,752 shares of the company's stock traded hands, compared to its average volume of 983,624. Alnylam Pharmaceuticals has a 12 month low of $205.87 and a 12 month high of $495.55. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The stock has a 50-day simple moving average of $458.98 and a 200 day simple moving average of $358.38. The stock has a market cap of $60.41 billion, a PE ratio of -187.06 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773.69 million for the quarter, compared to analysts' expectations of $633.54 million. During the same period last year, the business earned ($0.13) earnings per share. The business's quarterly revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Jeffrey V. Poulton sold 3,821 shares of the firm's stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the sale, the executive vice president owned 54,052 shares of the company's stock, valued at $24,434,206.60. This trade represents a 6.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the firm's stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,103,454.05. Following the completion of the sale, the executive vice president directly owned 25,231 shares of the company's stock, valued at $11,405,673.55. The trade was a 8.82% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,144 shares of company stock valued at $44,160,261 over the last three months. Insiders own 1.50% of the company's stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ALNY. Brighton Jones LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth $243,000. GAMMA Investing LLC raised its holdings in Alnylam Pharmaceuticals by 14.3% in the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company's stock worth $166,000 after purchasing an additional 77 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in Alnylam Pharmaceuticals by 14.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 14,404 shares of the biopharmaceutical company's stock worth $3,889,000 after purchasing an additional 1,838 shares in the last quarter. Lecap Asset Management Ltd. bought a new position in Alnylam Pharmaceuticals in the first quarter worth $461,000. Finally, Bessemer Group Inc. raised its holdings in Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.